| Stage | GE | % of rev | EMR | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $14.1B | 100.00% | $4.9B | 100.00% | GE ×2.90 |
| Gross profit | $5.0B | 35.57% | $2.7B | 54.48% | EMR +18.9pp |
| Operating income | $2.6B | 18.45% | $1.0B | 20.54% | EMR +2.1pp |
| Pre-tax income | $2.8B | 19.87% | $916M | 18.80% | GE +1.1pp |
| Net income | $2.3B | 16.26% | $718M | 14.73% | GE +1.5pp |
| Stage | GE | EMR | Gap · A − B |
|---|---|---|---|
| Revenue | $14.1B100.00% | $4.9B100.00% | GE ×2.90 |
| Gross profit | 35.57%$5.0B | 54.48%$2.7B | EMR +18.9pp |
| Operating income | 18.45%$2.6B | 20.54%$1.0B | EMR +2.1pp |
| Pre-tax income | 19.87%$2.8B | 18.80%$916M | GE +1.1pp |
| Net income | 16.26%$2.3B | 14.73%$718M | GE +1.5pp |
No disclosed counterparties: EMR.
None